Marvel Biosciences Corp. (MRVL.V)
- Newsfile
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model (FMR1) of Fragile X syndrome (FXS). Autism and FXS are closely related, often sharing clinical symptoms (e.g., developmental delays, challenges in so
- Newsfile
Marvel Biosciences Announces Stock Option Grants
Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce that, effective July 23, 2024, its board of directors approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,475,000 common shares in the capital of the Company at an exercise price of $0.125, being the closing price ...
- Newsfile
Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome
Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Merrer and Jerome Becker, lead investigators at the iBraiN Institute in Tours France. Building upon the promising results using MB204 in an autism model earlier this year, we now aim to test ...
